Trial Profile

A phase 2a study of R552 in patients with moderately to severely active rheumatoid arthritis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocadusertib (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

02 May 2023 According to a Rigel Pharmaceuticals media release, the trial is expected to begin in the second quarter of 2023.
12 Jan 2023 New trial record
09 Jan 2023 According to a Rigel Pharmaceuticals media release, the study analysis is expected by the end of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com